The stock of Uniqure NV (NASDAQ:QURE) hit a new 52-week low and has $6.25 target or 6.00% below today’s $6.65 share price. The 5 months bearish chart indicates high risk for the $154.36M company. The 1-year low was reported on Nov, 23 by Barchart.com. If the $6.25 price target is reached, the company will be worth $9.26M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 150,922 shares traded hands. Uniqure NV (NASDAQ:QURE) has declined 53.90% since April 21, 2016 and is downtrending. It has underperformed by 59.23% the S&P500.
Analysts await Uniqure NV (NASDAQ:QURE) to report earnings on December, 5. They expect $-0.86 EPS, down 14.67% or $0.11 from last year’s $-0.75 per share. After $-0.98 actual EPS reported by Uniqure NV for the previous quarter, Wall Street now forecasts -12.24% EPS growth.
Uniqure NV (NASDAQ:QURE) Ratings Coverage
Out of 11 analysts covering uniQure N.V. (NASDAQ:QURE), 8 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 73% are positive. uniQure N.V. has been the topic of 21 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Uniqure NV (NASDAQ:QURE) earned “Buy” rating by Roth Capital on Monday, November 30. The firm earned “Hold” rating on Tuesday, November 22 by Jefferies. On Tuesday, December 1 the stock rating was maintained by WallachBeth Capital with “Buy”. The stock of Uniqure NV (NASDAQ:QURE) earned “Neutral” rating by Piper Jaffray on Wednesday, November 16. TH Capital reinitiated Uniqure NV (NASDAQ:QURE) on Monday, November 30 with “Buy” rating. The stock has “Buy” rating given by H.C. Wainwright on Thursday, August 4. The rating was maintained by Oppenheimer with “Outperform” on Monday, September 21. The firm has “Buy” rating given on Thursday, August 27 by Chardan Capital Markets. The firm has “Neutral” rating by PiperJaffray given on Wednesday, November 16. The firm has “Buy” rating by Zacks given on Tuesday, September 1.
According to Zacks Investment Research, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.”
Another recent and important Uniqure NV (NASDAQ:QURE) news was published by Fool.com which published an article titled: “Why uniQure NV Stock Skyrocketed Today” on April 06, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.